ISR

Investor Moves

Name	Value	Action	Change	Price	Current Price
Steven CohenPoint72 $-16.0M ExitQ2 2024 $16M -- --
Ken GriffinCitadel Advisors $-14.6M ExitQ2 2024 $15M -- --
BlackRockInvestor $-9.4M ExitQ2 2024 $9.4M -- --

News

businesswire.comAIRO Debuts RQ-70 Long-Range ISR Drone Platform at Eurosatory 2026, Advancing Multi-Product Growth Strategybusinesswire.comJun 18

accessnewswire.comUr-Energy Celebrates 100th Shipment of Yellowcake from Lost Creek ISR Uranium Mine, Wyomingaccessnewswire.comJun 17

globenewswire.comEviden and Hexadrone combine their expertise to equip modular drones with SIGINT capabilitiesglobenewswire.comJun 16

globenewswire.comHaivision Introduces Play ISR Premium for Video Analysis, Collaboration, and Situational Awarenessglobenewswire.comJun 11

prnewswire.comUranium Energy Corp Reports Results for the Third Quarter of Fiscal 2026prnewswire.comJun 9

Trade ISR

About Isoray, Inc.

Isoray, Inc., operating through its subsidiary IsoRay Medical, Inc., specializes in the development, production, and sale of isotope-based medical devices and products. These offerings are designed for the treatment of cancer and other malignant diseases, distributed across both the United States and international markets. A key product is their CS-1 Cesium-131 brachytherapy seeds, utilized in addressing a variety of cancers, including those of the prostate, brain, lung, head and neck, as well as gynecological, pelvic/abdominal, and colorectal malignancies. The company distributes its products to medical facilities or physician practices that conduct surgical operations. Founded in 1998, Isoray, Inc. is headquartered in Richland, Washington.

CEO: Lori A. Holmes-Woods
IPO Date: May 31, 2002

Market Data

Open: $0.3724
High: $0.39
Low: $0.3613
Volume: 145K
Avg Volume: 257.3K
52W High: $0.45
52W Low: $0.19

Valuation

Market Cap: $0
Enterprise Value: $177M
Dividend Yield: 0.00%

Financials

Free Cash Flow: $-95M
Revenue: $0
Net Income: $-103M
Cash: $31M
Debt: $1.6M

Events

EarningsSep 30

actual -0.03691